Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

432.08 +9.76 (+2.31%)

Streaming Delayed Price Updated: 10:26 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

68 69 Next >

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Via MarketBeat

Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024 ↗

January 22, 2024

Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.

Via Talk Markets

A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist ↗

January 22, 2024

These stocks seem likely to keep up their winning ways.

Via The Motley Fool

Topics Stocks

10 Health Care Stocks Whale Activity In Today's Session ↗

January 22, 2024

Via Benzinga

Market Whales and Their Recent Bets on VRTX Options ↗

January 17, 2024

Via Benzinga

The Best Stock to Invest $1,000 in Right Now ↗

January 17, 2024

This stock has what it takes to be a big winner.

Via The Motley Fool

Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals ↗

January 11, 2024

Via Benzinga

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

January 22, 2024

Via Benzinga

If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today ↗

January 22, 2024

Has investing in Vertex been a better option than just putting your money in the S&P 500?

Via The Motley Fool

Topics Stocks

Cathie Wood's Flagship ARKK ETF Is Taking On Water Due To Coinbase, Tesla, These Stocks ↗

January 22, 2024

The flagship ETF's top holdings are down in 2024, especially No. 1 Coinbase.

Via Investor's Business Daily

Topics ETFs

2 Smart Growth Stocks to Buy Hand Over Fist in 2024 ↗

January 21, 2024

These businesses are on paths to extremely bright futures.

Via The Motley Fool

3 Unstoppable Growth Stocks That Can Make You Richer in 2024 ↗

January 20, 2024

These big winners of 2023 could keep their momentum going in the new year.

Via The Motley Fool

These 2 Phenomenal Growth Stocks Can Make You Richer in 2024 ↗

January 20, 2024

One market-beating stock and one beaten-down stock look like tempting buys for very different reasons.

Via The Motley Fool

3 High-Flying Stocks That Could Soar Even More in 2024 ↗

January 20, 2024

These big winners could keep the momentum going.

Via The Motley Fool

Vertex to Announce Fourth Quarter and Full Year 2023 Financial Results on February 5

January 17, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule ↗

January 17, 2024

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...

Via Benzinga

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock ↗

January 16, 2024

Shares of Vertex have risen exponentially since last month. Crispr stock, though, is meandering.

Via Investor's Business Daily

Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

January 16, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 16, 2024

Via Benzinga

Here's Why CRISPR Therapeutics Stock Rose 54% Last Year ↗

January 15, 2024

Key regulatory developments sent this biotech stock higher.

Via The Motley Fool

Down 88%, Could Editas Medicine Be a Good Investment Now? ↗

January 15, 2024

The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.

Via The Motley Fool

My 3 Highest-Conviction Growth Stocks to Buy in 2024 ↗

January 14, 2024

Simply put, these stocks inspire confidence.

Via The Motley Fool

3 Growth Stocks to Buy That Could Be Massive Long-Term Winners ↗

January 14, 2024

These stocks appear to have what it takes to keep up their winning ways.

Via The Motley Fool

3 Unstoppable Stocks to Buy in 2024 ↗

January 13, 2024

These stocks appear to be on a clear path to continued growth.

Via The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought This Week ↗

January 13, 2024

These companies could stand out thanks to game-changing technology.

Via The Motley Fool

Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades' ↗

January 12, 2024

On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda

Via Benzinga

3 Stocks to Buy in the Booming Field of Gene Editing ↗

January 11, 2024

As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.

Via InvestorPlace

Should Quality-Oriented Investors Explore VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)? ↗

January 11, 2024

Reasonable growth and debt and a high ROIC for VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX).

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 10, 2024

Via Benzinga

2 Red Flags for Bluebird Bio Stock ↗

January 10, 2024

The biotech's struggles may continue.

Via The Motley Fool

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.